Global R&D Pipeline
My Favorite
Hot Targets:
KLK7
Back
Total number of drugs
9
Phase II and later clinical stages
22.2%
Involving companies
9
Main therapeutic areas
Other Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPR-277 | BPR-277 | Small molecule drug | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | ELA2 inhibitors KLK7 inhibitors | Novartis Pharma AG | LifeMax Laboratories, Inc. | Phase 3 | - | - | - | - | Fast Track（United States） Orphan Drug（European Union） Orphan Drug（United States） Rare Pediatric Disease（United States） | - | - | - | - | BPR-277 | - | - | detail > | |
| TRIV-509 | TRIV-509 | Monoclonal antibody | Immune System Diseases Congenital Disorders Respiratory Diseases Skin and Musculoskeletal Diseases | KLK5 inhibitors KLK7 inhibitors | Triveni Bio, Inc. | Triveni Bio, Inc. | Phase 2 | - | - | - | - | - | - | - | - | - | TRIV-509 | - | - | detail > | |
| RO7449135 | RO7449135 | Bispecific antibody | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors KLK7 inhibitors | Genentech, Inc. | Genentech, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | RO7449135 | - | - | detail > | |
| TRIV-573 | TRIV-573 | Bispecific antibody | Digestive System Disorders Other Diseases | IL-13 inhibitors KLK5 inhibitors KLK7 inhibitors | Triveni Bio, Inc. | Triveni Bio, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | TRIV-573 | - | - | detail > | |
| Anti-KLK5/KLK7 bispecific antibody(Genentech) | Anti-KLK5/KLK7 bispecific antibody(Genentech) | Biological products | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors KLK7 inhibitors | Genentech, Inc. | Genentech, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | Anti-KLK5/KLK7 bispecific antibody(Genentech) | - | - | detail > | |
| BBP-561 | BBP-561 | Small molecule drug | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK5 inhibitors KLK7 inhibitors | BridgeBio Pharma, Inc. | - | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | - | BBP-561 | - | - | detail > | |
| KLK7 inhibitor(Asubio Pharma) | KLK7 inhibitor(Asubio Pharma) | Small molecule drug | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | KLK7 inhibitors | Asubio Pharma Co. Ltd. | - | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | - | KLK7 inhibitor(Asubio Pharma) | - | - | detail > | |
| SXR-1096 | SXR-1096 | Small molecule drug | Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases | KLK14 inhibitors KLK5 inhibitors KLK7 inhibitors | Sixera Pharma AB | - | Pending (in Phase 1/2) | - | - | - | - | Rare Pediatric Disease（United States） | - | - | - | - | SXR-1096 | - | - | detail > | |
| LEKTI-6 (Haemopep) | LEKTI-6 (Haemopep) | Recombinant protein | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | KLK5 inhibitors KLK7 inhibitors | Haemopep Pharma GmbH | - | Pending (in Discovery) | - | - | - | - | - | - | - | - | - | LEKTI-6 (Haemopep) | - | - | detail > |
Total 9 data
1
